Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPAP plus very early surfactant vs rescue surfactant in ≤30-week preterm infants
ChiCTR-IPR-16008753Phase 4Recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoints: Need for intubation within 72 hours and Statistical analysis using IBM SPSS 19.0. Started Jul 2016; status: recruiting.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on ChiCTR-IPR-16008753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008753.